RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
80 hedge funds and large institutions have $240M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2017 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 30 increasing their positions, 5 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
80
Holders Change
+23
Holders Change %
+40.35%
% of All Funds
2%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
26
Increased
30
Reduced
5
Closed
2
Calls
–
Puts
$376K
Net Calls
-$376K
Net Calls Change
-$376K
Top Buyers
| 1 |
BlackRock
New York
|
$27.9M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
$12.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
$20.9M |
| 4 |
Franklin Resources
San Mateo,
California
|
$7.78M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
$16.1M |
